Literature DB >> 1678963

Acute and chronic hemodynamic effects of drugs with different actions on adrenergic receptors: a comparison between alpha blockers and different types of beta blockers with and without vasodilating effect.

P Lund-Johansen1, P Omvik.   

Abstract

The regulation of vascular resistance, cardiac output, and thus blood pressure can be influenced by antihypertensive drugs acting at central and peripheral adrenergic receptors. The results presented here are from acute or chronic studies in 205 patients with mild or moderately severe essential hypertension: beta blockers (N = 101); alpha blockers (N = 36); a separate alpha- + beta-blocker combination or the combination agent labetalol (N = 37); prizidilol, a beta-blocker/vasodilator (N = 14); and dilevalol, a beta blocker/beta 2-stimulator (N = 17). Beta blockers without strong intrinsic sympathomimetic activity reduce heart rate and cardiac output immediately, but due to a reflex increase in total peripheral resistance index, blood pressure is unchanged or only slightly reduced. During chronic use, total peripheral resistance drops towards pretreatment level and pressure falls. Beta blockers with strong intrinsic sympathomimetic activity do not reduce heart rate or cardiac output at rest when sympathetic tone is low. During exercise, heart rate and cardiac output are reduced, but less than with conventional beta blockers, and resistance is unchanged or slightly reduced. An acute and chronic reduction in blood pressure can be produced by alpha-adrenergic receptor blockers (prazosin, doxazosin, trimazosin), and in these cases the fall occurs via a reduction in total peripheral resistance index without reflex tachycardia. These drugs tend to increase exercise stroke volume and cardiac output during chronic treatment. Free combinations of beta and alpha blockers or the use of the fixed combination drug, labetalol, induce marked reductions in blood pressure at rest and during exercise, mainly through a reduction in total peripheral resistance index. During chronic treatment, exercise stroke volume and cardiac output are well maintained. In acute studies with dilevalol, systolic blood pressure, diastolic blood pressure, and mean arterial pressure were reduced (p less than 0.001) within 1 hour in 17 males with essential hypertension (WHO stage I) who received 200-400 mg oral dilevalol. The reduction in MAP was around 16-17% and was associated with an immediate fall in the total peripheral resistance index of the same magnitude (14%, p less than 0.001) after 1 hour at rest. There were no significant changes in heart rate or cardiac index.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1678963     DOI: 10.1007/bf03029729

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  29 in total

1.  Haemodynamic adaptation at rest and during exercise to long-term antihypertensive treatment with combined alpha- and beta-adrenoreceptor blockade by labetalol.

Authors:  G Koch
Journal:  Br Heart J       Date:  1979-02

Review 2.  The fourth Sir George Pickering memorial lecture. The structure of the resistance vasculature in essential hypertension.

Authors:  M J Mulvany
Journal:  J Hypertens       Date:  1987-04       Impact factor: 4.844

3.  Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study.

Authors:  J Wikstrand; I Warnold; G Olsson; J Tuomilehto; D Elmfeldt; G Berglund
Journal:  JAMA       Date:  1988-04-01       Impact factor: 56.272

4.  Haemodynamic effects and plasma concentrations of labetalol during long-term treatment of essential hypertension.

Authors:  P Lund-Johansen; O M Bakke
Journal:  Br J Clin Pharmacol       Date:  1979-02       Impact factor: 4.335

Review 5.  Hemodynamic aspects of essential hypertension in humans.

Authors:  J Conway
Journal:  Physiol Rev       Date:  1984-04       Impact factor: 37.312

6.  Acute and long-term effects of labetalol on systemic and pulmonary haemodynamics in hypertensive patients.

Authors:  T L Svendsen; S Rasmussen; O J Hartling; P E Nielsen; J Trap-Jensen
Journal:  Eur J Clin Pharmacol       Date:  1980-01       Impact factor: 2.953

7.  Effect of beta-adrenoceptor blockade on exercise performance and metabolism.

Authors:  P Lundborg; H Aström; C Bengtsson; E Fellenius; H von Schenck; L Svensson; U Smith
Journal:  Clin Sci (Lond)       Date:  1981-09       Impact factor: 6.124

8.  Haemodynamic effects of long-term oral labetalol.

Authors:  R C Edwards; E B Raftery
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

9.  Short- and long-term (six-year) hemodynamic effects of labetalol in essential hypertension.

Authors:  P Lund-Johansen
Journal:  Am J Med       Date:  1983-10-17       Impact factor: 4.965

10.  Prizidilol in essential hypertension: long-term effects on plasma volume, extracellular fluid volume, and central hemodynamics at rest and during exercise.

Authors:  P Lund-Johansen; P Omvik
Journal:  J Cardiovasc Pharmacol       Date:  1982 Nov-Dec       Impact factor: 3.105

View more
  13 in total

Review 1.  Formulary considerations in selection of beta-blockers.

Authors:  K C Yedinak
Journal:  Pharmacoeconomics       Date:  1993-08       Impact factor: 4.981

2.  Comparison of the hemodynamic effects of metoprolol and carvedilol in hypertensive patients.

Authors:  K Weber; T Bohmeke; R van der Does; S H Taylor
Journal:  Cardiovasc Drugs Ther       Date:  1996-05       Impact factor: 3.727

Review 3.  Cardiac alpha1-adrenergic receptors: novel aspects of expression, signaling mechanisms, physiologic function, and clinical importance.

Authors:  Timothy D O'Connell; Brian C Jensen; Anthony J Baker; Paul C Simpson
Journal:  Pharmacol Rev       Date:  2013-12-24       Impact factor: 25.468

4.  Long-term hemodynamic effects at rest and during exercise of newer antihypertensive agents and salt restriction in essential hypertension: review of epanolol, doxazosin, amlodipine, felodipine, diltiazem, lisinopril, dilevalol, carvedilol, and ketanserin.

Authors:  P Omvik; P Lund-Johansen
Journal:  Cardiovasc Drugs Ther       Date:  1993-04       Impact factor: 3.727

5.  Modest antihypertensive effect of epanolol, a beta 1-selective receptor blocker with beta 1 agonist activity: an acute and long-term hemodynamic study at rest and during exercise and double crossover comparison with atenolol on ambulatory blood pressure.

Authors:  P Omvik; P Lund-Johansen; H Haugland
Journal:  Cardiovasc Drugs Ther       Date:  1993-02       Impact factor: 3.727

Review 6.  Effects of tobacco constituents and psychological stress on the beta-adrenergic regulation of non-small cell lung cancer and pancreatic cancer: implications for intervention.

Authors:  Hildegard M Schuller
Journal:  Cancer Biomark       Date:  2013       Impact factor: 4.388

7.  Single and repeated doses of the vasodilator/beta-adrenergic antagonist, carvedilol, block cirazoline- and isoproterenol-mediated hemodynamic responses in the conscious rat.

Authors:  E F Smith; M J Slivjak; R Gagnon
Journal:  Cardiovasc Drugs Ther       Date:  1992-10       Impact factor: 3.727

Review 8.  Alpha1-adrenergic blockers: current usage considerations.

Authors:  Domenic A Sica
Journal:  J Clin Hypertens (Greenwich)       Date:  2005-12       Impact factor: 3.738

Review 9.  Circulatory therapeutics: use of antihypertensive agents and their effects on the vasculature.

Authors:  Ernesto L Schiffrin
Journal:  J Cell Mol Med       Date:  2010-03-19       Impact factor: 5.310

10.  Acute effects of intravenous dronedarone on electrocardiograms, hemodynamics and cardiac functions in anesthetized dogs.

Authors:  Nakkawee Saengklub; Vudhiporn Limprasutr; Suwanakiet Sawangkoon; Chollada Buranakarl; Robert L Hamlin; Anusak Kijtawornrat
Journal:  J Vet Med Sci       Date:  2015-09-04       Impact factor: 1.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.